Monthly Archives: June 2018

INTIVA BioPharma Files a U.S. Patent Application for the Use of Cannabinoids for Treating Myotonia, Myotonic Dystrophy and Other Related Dystrophies

DENVER, CO / ACCESSWIRE / June 28, 2018 / INTIVA BioPharma Inc. (“INTIVA” or the “Company”) (OTC PINK: NTVA) announced that it has filed a utility patent application with the United States Patent Office relating to the use of cannabinoids to treat myotonia, myotonic dystrophy and other related dystrophies. The patent application addresses methods and compositions for treating the diseases and covers the administration of the formulation by various delivery systems. This utility patent application claims the benefit of a provisional patent application that was filed by the Company in 2017.

Myotonia refers to a neuromuscular condition in which the relaxation of a muscle is impaired and can affect any muscle group. Because a repeated effort is required to relax the muscle, individuals with myotonia may have trouble with normal activities including releasing their grip on objects and having difficulty rising from a seated position. Patients suffering from myotonia often walk with a stiff, awkward gait.

Myotonic dystrophy is a genetic disorder that affects muscular function. Symptoms include gradually worsening muscle loss and weakness. There is currently no cure for myotonic dystrophy; however, various drugs have been administered to manage various symptoms without great success.

Rob Goldfarb, INTIVA Chief Operating Officer stated, “We are excited about the prospect of developing a cannabinoid-based drug to treat the devastating and debilitating symptoms of myotonia, myotonic dystrophy and certain other dystrophies. We are hopeful that INTIVA’s drug development strategies to treat these disorders will be instrumental in developing cannabinoid-based medical treatments that will be compliant with U.S. Food and Drug Administration (“FDA”) requirements”.

The market intelligence firm, EvaluatePharm® estimated that the mean cost per patient during 2017 in the United States for non‑orphan drugs was $30,708 and that the median cost per patient for non‑orphan drugs was $15,809. The firm also projected that sale for the overall pharmaceutical market should grow at 6.4% per year.

Alain Bankier, INTIVA’s Interim CEO added “With the current patient population of myotonia, myotonic dystrophy and other related dystrophies estimated to be in excess of one incidence per 8,000 people, and assuming we will be able to produce cannabinoid-based medicine, at or below the median cost of drugs for patient care, it is anticipated that the potential market for new solutions to treat these patients could represent a significant opportunity, while helping many people afflicted with these debilitating symptoms”.

About INTIVA BioPharma Inc.

INTIVA BioPharma Inc. is a US-based pharmaceutical company engaged in the formulation, development and commercialization of cannabinoid-based pharmaceuticals, in accordance with U.S. Food and Drug Administration (“FDA”) pre-clinical and clinical pathways, to address a broad range of medical conditions and disorders.

INTIVA BioPharma’s drug development strategy consists of:

A. The determination of medical conditions and disorders that could potentially benefit from cannabinoid-based formulations;

B. Conducting “freedom to operate” investigations on these conditions;

C. The preparation of patent applications and the prosecution of such application and/or the licensing of existing patents;

D. Identifying the regulatory pathway with the FDA; and

E. Proceeding with pre-clinical and clinical development activities in accordance with FDA protocols for submission to obtain approval for the particular product(s).

INTIVA BioPharma website: www.intivabiopharma.com.

INTIVA Disclosure Notice: This press release contains “forward-looking statements. For this purpose, any statements contained herein or which are otherwise made by or on behalf of INTIVA BioPharma that are not statements of historical facts may be deemed forward-looking statements. Without limiting the generality of the foregoing, words such as “may,””will,””to,””plan,””expect,””believe,””anticipate,””intend,””could,””should,””would,””estimate,” or “continue,” or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements. Readers are cautioned that all forward-looking statements involve risk and uncertainties which may cause results to differ materially from those set forth in the statements. Such risks and uncertainties include, but are not limited to the following: the success of research and development activities and the speed with which regulatory authorizations and product launches may be achieved; government regulation generally; competitive developments; the ability to successfully market products domestically and internationally; difficulties or delays in manufacturing or issues relating to manufacturing capacity; commercial obstacles to the successful introduction of brand products generally; legal defense costs, insurance expenses, settlement costs, and the risk of an adverse decision or settlement relating to product liability, patent protection, governmental investigations, and other legal proceedings; INTIVA BioPharma’s ability to acquire and protect patents and other intellectual property both domestically and internationally; the absence of certainty regarding the receipt of required regulatory approval or the timing or terms of such approvals; any changes in business, political and economic conditions; business interruption due to hurricanes or other events outside of INTIVA BioPharma’s control.

Readers are cautioned not to place reliance on these forward-looking statements, which are valid only as of the date they were made. INTIVA BioPharma undertakes no obligation to update or revise any forward-looking statements to reflect new information or the occurrence of unanticipated events or otherwise, except as expressly required by law.

Contact:

Mark Lubchenco
Director of Investor Relations
303 495 7583
mlubchenco@intivabiopharma.com
www.INTIVABiopharma.com

SOURCE: Intiva Biopharma Inc.

ReleaseID: 504066

TechPrecision Corporation Reports Financial Results for Fiscal 2018

Company Achieves Third Consecutive Year of Pretax Profit

WESTMINSTER, MA / ACCESSWIRE / June 28, 2018 / TechPrecision Corporation (OTCQB: TPCS) (“TechPrecision” or “the Company”), an industry leading manufacturer of precision, large-scale fabricated and machined metal components and tested systems with customers in the defense, energy and precision industrial sectors, today reported financial results for the fourth quarter and the full year ended March 31, 2018. Net sales for the three months ended March 31, 2018 were $4.7 million, a 5% decrease when compared to the same quarter a year ago. Net sales for the fiscal year ended March 31, 2018 were $18.7 million, a 1% increase when compared to the same period a year ago. Sales order backlog at March 31, 2018 was $14.0 million compared with backlog of $15.8 million at March 31, 2017 and $11.2 million at December 31, 2017. Gross profit for the fourth quarter and full year of fiscal 2018 were significantly lower when compared to the same periods a year ago.

“This was another year of operational execution, resulting in our third consecutive year of pretax profitability,” stated Alexander Shen, TechPrecision’s Chief Executive Officer. “Our results were impacted by lower gross margins for fiscal 2018, which were primarily the result of higher amounts of unabsorbed overhead related to a slowdown in the number of projects in production. Additionally, we experienced a higher volume of low margin components shipped during the period. We expect to return to levels of project activity during fiscal 2019 that are more consistent with our prior year results of operations.”

Fourth Quarter of Fiscal 2018 Financial Results

Net sales were $4.7 million, a $263,000 decrease when compared to the same quarter a year ago.
Gross profit was $380,000 compared to $1.0 million in the same quarter last year, a 63% decrease, primarily on a higher volume of low margin sales mix and under absorbed overhead from a slowdown in project activity, caused by defense customer funding delays.
Operating loss was $393,000 compared to operating income of $281,000 in the same period a year ago.
Net loss was $367,000 or $0.01 per diluted share, compared to net income of $3.1 million, or $0.11 per diluted share, in the year-ago quarter. Fourth quarter fiscal 2017 included a net tax benefit of $2.9 million, primarily the result of the release of a valuation allowance on specific deferred tax assets.

Full Year Fiscal 2018 Financial Results

Net sales were $18.7 million, a 1% increase when compared to the same period a year ago.
Gross profit was $4.0 million, a 35% decrease compared to $6.1 million in the same period a year ago, primarily due to a higher volume of low margin sales mix and under absorbed overhead.
Operating income was $1.0 million, compared to operating income of $2.9 million in the same period a year ago. Fiscal 2017 included a one-time gain for $1.1 million from a customer assignment settlement.
Interest expense was $413,000 and $644,000 for fiscal 2018 and fiscal 2017, respectively. The decrease in interest expense is primarily due to lower interest rates in connection with the debt refinancing transactions completed in fiscal 2017.
Pretax profit was $559,000 for fiscal 2018 compared to $2.2 million in fiscal 2017.
Net loss was $266,000 or $0.01 per diluted share, compared to net income of $5.1 million or $0.18 per diluted share in the same period last year. Fiscal 2018 included a one-time, non-cash charge of $0.7 million related to the change in the U.S. statutory tax rate as provided under the Tax Cuts and Jobs Act. Fiscal 2017 included a one-time favorable benefit of $2.8 million related to a tax valuation allowance release.
EBITDA was $1.7 million for the year ended March 31, 2018, compared to $3.6 million for the year ended March 31, 2017. Please refer to the reconciliation of EBITDA (a non-GAAP measure) to net income (a GAAP measure) in this release.

Financial Position

At March 31, 2018, TechPrecision had $2.7 million in cash, and working capital of $4.9 million compared to $3.1 million in cash and working capital of $5.0 million at March 31, 2017

Income Taxes

For the year ended March 31, 2018 the Company recorded tax expense of $824,000. This tax expense includes a $700,000 non-cash item, the result of a revaluation of the Company’s estimated net deferred tax assets to reflect the new 21% U.S. statutory tax rate as provided under the Tax Cuts and Jobs Act, recently enacted on December 22, 2017. Cash paid for income taxes was $32,000 for the full year ended March 31, 2018.

Teleconference Information

The Company will hold a conference call at 4:30 p.m. Eastern (U.S.) time on June 28, 2018. To participate in the live conference call, please dial 1-877-407-8133 five to 10 minutes prior to the scheduled conference call time. International callers should dial 1-201-689-8040. When prompted, reference TechPrecision.

A replay will be available until July 28, 2018. To access the replay, dial 1-877-481-4010 or 1-919-882-2331. When prompted, enter Conference Passcode 33509. The call will also be available live by webcast at TechPrecision Corporation’s website, www.techprecision.com, and will also be available over the Internet and accessible at http://www.investorcalendar.com/event/33509.

About TechPrecision Corporation

TechPrecision Corporation, through its wholly owned subsidiaries, Ranor, Inc. and Wuxi Critical Mechanical Components Co., Ltd., manufactures large-scale, metal fabricated and machined precision components and equipment. These products are used in a variety of markets including: defense, aerospace, nuclear, industrial, and medical. TechPrecision’s goal is to be an end-to-end service provider to its customers by furnishing customized solutions for completed products requiring custom fabrication and machining, assembly, inspection and testing. To learn more about the Company, please visit the corporate website at http://www.techprecision.com. Information on the Company’s website or any other website does not constitute a part of this press release.

Safe Harbor Statement

This release contains certain “forward-looking statements” relating to the business of the Company and its subsidiary companies. All statements other than statements of current or historical fact contained in this press release, including statements that express our intentions, plans, objectives, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions are forward-looking statements. These forward-looking statements are often identified by the use of forward-looking terminology such as “believe,” “continue,” “expect,” “will” or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including our reliance on individual purchase orders, rather than long-term contracts, to generate revenue, our ability to change the composition of our revenues and effectively reduce operating expenses, the availability of appropriate financing facilities impacting our operations, financial condition and/or liquidity, our ability to receive contract awards through competitive bidding processes, our ability to maintain standards to enable us to manufacture products to exacting specifications, our ability to enter new markets for our services, our reliance on a small number of customers for a significant percentage of our business, competitive pressures in the markets we serve, changes in the availability or cost of raw materials and energy for our production facilities, operating in a single geographic location, restrictions in our ability to operate our business due to our outstanding indebtedness, government regulations and requirements, pricing and business development difficulties, changes in government spending on national defense, our ability to make acquisitions and successfully integrate those acquisitions with our business and other risks discussed in the Company’s periodic reports that are filed with the Securities and Exchange Commission and available on its website (www.sec.gov). All forward-looking statements attributable to the Company or to persons acting on its behalf are expressly qualified in their entirety by these factors. Any forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to publicly update or revise any forward-looking statements to reflect events or circumstances that may arise after the date of this press release, except as required by applicable law.

CONTACT:

Hayden IR
Brett Maas
Phone: 646-536-7331
Email: brett@haydenir.com
Website: www.haydenir.com

Company Contact
Mr. Thomas Sammons, Chief Financial Officers
TechPrecision Corporation
Phone: 978-883-5109
Email: sammonst@ranor.com
Website: www.techprecision.com

TECHPRECISION CORPORATION
CONSOLIDATED BALANCE SHEETS

March 31,

2018

March 31,

2017

ASSETS

Current assets:

Cash and cash equivalents

$

2,689,110

$

3,066,156

Accounts receivable, net

1,794,878

1,870,672

Costs incurred on uncompleted contracts, in excess of progress billings

1,885,748

2,097,221

Inventories – raw materials

202,737

141,792

Other current assets

450,540

422,096

Total current assets

7,023,013

7,597,937

Property, plant and equipment, net

5,202,448

4,912,202

Deferred income taxes

2,046,298

2,871,680

Other noncurrent assets, net

6,860

100,000

Total assets

$

14,278,619

$

15,481,819

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities:

Accounts payable

$

345,705

$

365,308

Accrued expenses

788,084

893,415

Billings on uncompleted contracts, in excess of related costs

180,706

642,831

Current portion of long-term debt

766,354

717,481

Total current liabilities

2,080,849

2,619,035

Long-term debt, including capital leases

4,185,274

4,874,721

Noncurrent accrued expenses

17,742

Stockholders’ Equity:

Common stock – par value $.0001 per share, 90,000,000 shares authorized,
28,824,593 shares issued and outstanding at March 31, 2018 and 2017

2,882

2,882

Additional paid in capital

8,561,995

8,258,820

Accumulated other comprehensive income

24,236

19,328

Accumulated deficit

(576,617

)

(310,709

)

Total stockholders’ equity

8,012,496

7,970,321

Total liabilities and stockholders’ equity

$

14,278,619

$

15,481,819

TECHPRECISION CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)

Three Months Ended

March 31,

Twelve Months Ended

March 31,

2018

2017

2018

2017

Net sales

$

4,668,420

$

4,931,096

$

18,729,994

$

18,550,674

Cost of sales

4,288,458

3,895,862

14,753,693

12,454,542

Gross profit

379,962

1,035,234

3,976,301

6,096,132

Selling, general and administrative

772,631

754,131

3,009,002

4,336,987

Gain from claims assignment settlement

(1,122,287

)

Income (loss) from operations

(392,669

)

281,103

967,299

2,881,432

Other income

2,634

(266

)

4,267

8,439

Interest expense

(98,931

)

(60,022

)

(412,988

)

(644,021

)

Total other expense, net

(96,297

)

(60,288

)

(408,721

)

(635,582

)

Income (loss) before income taxes

(488,966

)

220,815

558,578

2,245,850

Income tax expense (benefit)

(121,761

)

(2,875,875

)

824,486

(2,834,319

)

Net (loss) income

$

(367,205

)

$

3,096,690

$

(265,908

)

$

5,080,169

Other comprehensive income (loss), before tax:

Foreign currency translation adjustments

1,721

78

4,908

(2,240

)

Tax expense (benefit)

(1,006

)

Other comprehensive income (loss), net of tax

2,727

78

4,908

(2,240

)

Comprehensive (loss) income

$

(364,478

)

$

3,096,768

$

(261,000

)

$

5,077,929

Net (loss) income per share basic

$

(0.01

)

$

0.11

$

(0.01

)

$

0.18

Net (loss) income per share diluted

$

(0.01

)

$

0.11

$

(0.01

)

$

0.18

Weighted average number of shares outstanding basic

28,824,593

28,156,115

28,824,593

27,908,155

Weighted average number of shares outstanding diluted

28,824,593

29,112,083

28,824,593

28,611,074

TECHPRECISION CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS

Years Ended March 31,

2018

2017

CASH FLOWS FROM OPERATING ACTIVITIES

Net (loss) income

$

(265,908

)

$

5,080,169

Adjustments to reconcile net income to net cash provided by operating activities:

Depreciation

704,284

689,293

Amortization of debt issue costs

70,041

101,280

Loss on disposal of equipment

20,000

62,140

Stock based compensation expense

303,175

1,164,221

Change in contract losses

52,197

(304,465

)

Deferred income taxes

825,382

(2,871,680

)

Gain from claims assignment settlement – noncash portion

(507,835

)

Changes in operating assets and liabilities:

Accounts receivable

75,794

151,808

Costs incurred on uncompleted contracts, in excess of related billings

211,473

298,421

Inventories – raw materials

(60,945

)

(13,197

)

Other current assets

(28,443

)

108,692

Other noncurrent assets and liabilities

(17,742

)

7,978

Accounts payable

(19,603

)

(630,757

)

Accrued expenses

(151,401

)

(611,076

)

Accrued taxes payable

(9,032

)

Billings on uncompleted contracts, in excess of related costs

(462,125

)

(986,187

)

Net cash provided by operating activities

1,256,179

1,729,773

CASH FLOWS FROM INVESTING ACTIVITIES

Purchases of property, plant and equipment

(994,530

)

(787,808

)

Proceeds from sale of equipment

80,000

Net cash used in investing activities

(914,530

)

(787,808

)

CASH FLOWS FROM FINANCING ACTIVITIES

Deferred loan costs

(198,449

)

Borrowings of long-term debt

6,227,500

Repayment of capital lease obligation

(19,940

)

(13,684

)

Repayment of long-term debt

(697,536

)

(5,222,933

)

Net cash (used in) provided by financing activities

(717,476

)

792,434

Effect of exchange rate on cash and cash equivalents

(1,219

)

(409

)

Net (decrease) increase in cash and cash equivalents

(377,046

)

1,733,990

Cash and cash equivalents, beginning of period

3,066,156

1,332,166

Cash and cash equivalents, end of period

$

2,689,110

$

3,066,156

TECHPRECISION CORPORATION
SUPPLEMENTAL INFORMATION
Reconciliation of EBITDA to Net Income (loss)

The following table provides a reconciliation of EBITDA to net income, the most directly comparable U.S. GAAP measure reported in our condensed consolidated financial statements:

Twelve months

ended

March 31,

2018

Twelve months

ended

March 31,

2017

Change

Amount

Net income (loss)

$

(265,908

)

$

5,080,169

$

(5,346,077

)

Income tax expense

824,486

(2,834,319

)

3,658,805

Interest expense (1)

412,988

644,021

(231,033

)

Depreciation

704,284

689,293

14,991

EBITDA

$

1,675,850

$

3,579,164

$

(1,903,314

)

(1) Includes amortization of debt issue costs.

SOURCE: TechPrecision Corporation

ReleaseID: 504034

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ormat Technologies, Inc. – ORA

NEW YORK, NY / ACCESSWIRE / June 28, 2018 / Pomerantz LLP is investigating claims on behalf of investors of Ormat Technologies, Inc. (“Ormat” or the “Company”) (NYSE: ORA). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

The investigation concerns whether Ormat and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here to join a class action]

On May 11, 2018, Ormat disclosed that the Company was delaying the filing of its Quarterly Report for the period ended March 31, 2018 with the U.S. Securities and Exchange Commission, stating that “management has identified an error in the Company’s financial statement presentation of deferred income tax assets and deferred income tax liabilities that affect the Company’s balance sheets in previous reporting periods.” Ormat further disclosed that “[t]he Company is evaluating the impact of this error on its consolidated financial statements and the extent to which the Company’s annual and quarterly consolidated financial statements filed in previous periods require revision or amendment.” On this news, Ormat’s share price fell $3.58, or over 6%, over two consecutive trading days to close at $52.77 on May 14, 2018. Then, on May 16, 2018, Ormat announced that the Company “will restate its second, third and fourth quarter 2017 financial statements and its full-year 2017 financial statements,” and stated that “investors should no longer rely upon the Company’s previously issued financial statements for [these] periods . . . , earnings releases for these periods, and other communications relating to these financial statements.” On this news, Ormat’s share price fell $0.67, or 1.26%, to close at $52.35 on May 16, 2018.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

SOURCE: Pomerantz LLP

ReleaseID: 504059

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in PG&E Corporation of Class Action Lawsuit and Upcoming Deadline – PCG

NEW YORK, NY / ACCESSWIRE / June 28, 2018 / Pomerantz LLP announces that a class action lawsuit has been filed against PG&E Corporation. (“PG&E” or the “Company”) (NYSE: PCG) and certain of its officers. The class action, filed in United States District Court, Northern District of California, and docketed under 18-cv-03545, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise acquired securities of PG&E between April 29, 2015 and June 8, 2018, both dates inclusive (the “Class Period”). Plaintiff seeks to recover compensable damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder.

If you are a shareholder who purchased PG&E securities between April 29, 2015, and June 8, 2018, both dates inclusive, you have until August 13, 2018, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

[Click here to join this class action]

PG&E is a holding company that holds interests in energy-based businesses. The Company’s leading operating subsidiary is Pacific Gas and Electric Company, a public utility operating in northern and central California that provides electricity and natural gas distribution, electricity generation, procurement, and transmission, and natural gas procurement, transportation, and storage. The Company generates revenues mainly through the sale and delivery of electricity and natural gas to customers.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) PG&E had failed to maintain electricity transmission and distribution networks in compliance with safety requirements and regulations promulgated under state law; (ii) consequently, PG&E was in violation of state laws and regulations; (iii) PG&E’s noncompliant electricity networks could foreseeably cause wildfires in California; and (iv) as a result of the foregoing, Defendants’ statements about the Company’s business and operations were materially false and misleading at all relevant times.

On June 8, 2018, after the market close, the California Department of Forestry and Fire Protection issued a press release announcing the cause of twelve wildfires in Mendocino, Humboldt, Butte, Sonoma, Lake, and Napa Counties involving equipment owned by PG&E.

The press release stated that CAL FIRE Investigators had determined “that 12 Northern California wildfires in the October 2017 Fire Siege were caused by electric power and distribution lines, conductors and the failure of power poles,” and referred “eight of the 12 fires — Sulphur, Blue, Norrbom, Partrick, Pythian, Adobe, Pocket and Atlas” to the county District Attorney’s offices for review “due to evidence of alleged violations of state law.

On June 9, 2018, Bloomberg published an article entitled “PG&E May Face Criminal Charges After Probe of Deadly Wildfires.” The article reported, in part, that following an investigation into the causes of wildfires “that altogether killed 44 people, consumed thousands of homes and racked up an estimated $10 billion in damages” in October 2017, California’s fire agency “found evidence of alleged violations of law by PG&E in connection with” the fires. Specifically, the state’s investigation found “that PG&E equipment caused at least 12 of the wine country blazes.”

Following this news, PG&E’s share price fell $1.69, or 4.08%, to close at $39.76 on June 11, 2018, the following trading day.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

SOURCE: Pomerantz LLP

ReleaseID: 504040

Kessler Topaz Meltzer & Check, LLP: Final Deadline Reminder for LendingClub Corporation Investors – LC

RADNOR, PA / ACCESSWIRE / June 28, 2018 / Kessler Topaz Meltzer & Check, LLP reminds LendingClub Corporation (NYSE: LC) (“LendingClub”) investors that a class action lawsuit has been filed on behalf of purchasers of LendingClub publicly traded securities between February 28, 2015 and April 25, 2018, inclusive (the “Class Period”).

FINAL REMINDER: Investors who purchased LendingClub securities during the Class Period may, no later than July 2, 2018, seek to be appointed as a lead plaintiff representative of the class. For additional information or to learn how to participate in this action please visit https://www.ktmc.com/new-cases/lendingclub-corporation-2018#join

According to the complaint, LendingClub operates an online marketplace platform that connects borrowers and investors in the United States.

The Class Period begins on February 28, 2015, the day after LendingClub filed its annual report on Form 10-K for the year ended December 31, 2014 (“2014 10-K”) with the SEC which provided LendingClub’s annual financial results and position. The 2014 10-K stated LendingClub believed that all installment loans offered through its marketplace featured a fixed rate that was “clearly” disclosed to the borrower and which contained “no hidden fees.”

On April 25, 2018, the Federal Trade Commission (“FTC”) announced in a press release that it had filed a complaint against LendingClub alleging violations of, inter alia, the FTC Act for falsely promising consumers they would receive a loan with “no hidden fees[,]” and the Gramm-Leach-Bliley Act for failing to provide customers with a clear and conspicuous privacy notice so that each customer could reasonably be expected to receive actual notice. The press release stated, in relevant part: “The Federal Trade Commission has charged the LendingClub Corporation with falsely promising consumers they would receive a loan with “no hidden fees,” when, in actuality, the company deducted hundreds or even thousands of dollars in hidden up-front fees from the loans.”

Following this news, shares of LendingClub fell $.49 per share, or over 15% from its previous closing price to close at $2.77 per share on April 25, 2018.

The complaint alleges that, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) LendingClub falsely promised consumers they would receive a loan with “no hidden fees”; (2) LendingClub’s privacy policy did not comply with the Gramm-Leach-Bliley Act; (3) consequently, the foregoing conduct would subject LendingClub’s business practices to heightened regulatory scrutiny by the Federal Trade Commission; and (4) as a result, defendants’ public statements were materially false and misleading at all relevant times.

LendingClub investors who wish to discuss their legal rights or interests with respect to this action are encouraged to contact Kessler Topaz Meltzer & Check (James Maro, Jr., Esq. or Adrienne Bell, Esq.) at (888) 299 – 7706 or (610) 667 – 7706, or via e-mail at info@ktmc.com.

LendingClub investors may, no later than July 2, 2018, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. In order to be appointed as a lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members, and that the class member will adequately represent the class in the action. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.

Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country involving securities fraud, breaches of fiduciary duties and other violations of state and federal law. Kessler Topaz Meltzer & Check, LLP is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world. The firm represents investors, consumers and whistleblowers (private citizens who report fraudulent practices against the government and share in the recovery of government dollars). For more information about Kessler Topaz Meltzer & Check, LLP, please visit www.ktmc.com.

CONTACT:

Kessler Topaz Meltzer & Check, LLP
James Maro, Jr., Esq.
Adrienne Bell, Esq.
280 King of Prussia Road
Radnor, PA 19087
(888) 299-7706
(610) 667-7706
info@ktmc.com

SOURCE: Kessler Topaz Meltzer & Check, LLP

ReleaseID: 504061

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Gogo Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / June 28, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Gogo Inc. (“Gogo” or the “Company”) (NASDAQ: GOGO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Gogo announced its first quarter 2018 financial results before the market opened on May 4, 2018. The Company disclosed that it was “withdrawing its previously provided 2018 guidance for Adjusted EBITDA, airborne Cash CAPEX, and airborne equipment inventory purchases related to airline-directed installations, as well as Free Cash Flow guidance.” Based on this announcement, shares of Gogo fell 18%, or $1.73 per share, over the next two trading sessions. Moody’s downgraded Gogo’s rating on May 7, resulting in a 35% share price drop on May 8, 2018.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall, or Sherin Mahdavian, of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.
Sherin Mahdavian, Esq.

SOURCE: The Schall Law Firm

ReleaseID: 504043

NIKE, Inc. Class B to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / June 28, 2018 / NIKE, Inc. Class B (NYSE: NKE) will be discussing their earnings results in their Q4 Earnings Call to be held on June 28, 2018 at 5:00 PM Eastern Time.

To listen to the event live or access a replay of the call – visit https://www.investornetwork.com/company/1279

To receive updates for this company you can register by emailing info@investornetwork.com or by clicking get investment info from the company’s profile.

About Investor Network

Investor Network (IN) is a financial content community, serving millions of unique investors market information, earnings, commentary and news on the what’s trending. Dedicated to both the professional and the average traders, IN offers timely, trusted and relevant financial information for virtually every investor. IN is an Issuer Direct brand, to learn more or for the latest financial news and market information, visit www.investornetwork.com. Follow us on Twitter @investornetwork.

SOURCE: Investor Network

ReleaseID: 503655

NEW INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against National Beverage Corp. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / June 28, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of National Beverage Corp. (“National Beverage” or the “Company”) (NASDAQ: FIZZ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. National Beverage issues a press release on May 4, 2018, claiming that it, “employs methods that no other company does in this area—VPO (velocity per outlet) and VPC (velocity per capita).” The press release also claimed the Company, “utilize[s] two proprietary techniques to magnify these measures and this creates growth never before thought possible.” National Beverage issued a second press release the next day which claimed, “[o]ur impressive VPO calculator . . . is flashing solid green numbers as we bring FY2017 to a close.” The Wall Street Journal published an article on June 26, 2018, titled “The SEC Has Had Its Own Questions About LaCroix,” which reported that National Beverage “declined to provide” the SEC with information requested by the agency “with requested figures to clarify [National Beverage’s] sales claims,” which the SEC sought in a letter to the Company in January. Based on this report, shares in National Beverage fell significantly during intraday trading on June 27, 2018.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall, or Sherin Mahdavian, of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.
Sherin Mahdavian, Esq.

SOURCE: The Schall Law Firm

ReleaseID: 504047

IMPORTANT DEADLINE NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Esperion Therapeutics, Inc. and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / June 28, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Esperion Therapeutics, Inc. (“Esperion” or ”the Company”) (NASDAQ: ESPR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s shares between February 22, 2017, and May 1, 2018, inclusive (the ”Class Period”), are encouraged to contact the firm before July 6, 2018.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall, or Sherin Mahdavian, of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, Esperion Therapeutics made materially false and misleading statements during the class period. Esperion failed to disclose that Bempedoic acid, the company’s cholesterol-lowering medication, had serious safety risks up to and including death. As a result of the failure to disclose this information, Esperion Therapeutics’ financial statements, claims about the company’s business operations, and financial prospects were materially false and misleading throughout the class period. According to the lawsuit, when accurate information about Esperion Therapeutics became apparent in the market, investors suffered damages.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.
Sherin Mahdavian, Esq.
www.schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 504050

SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against PolarityTE, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / June 28, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PolarityTE, Inc. (“PolarityTE” or the “Company”) (NASDAQ: COOL) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. On June 25, 2018, Citron Research released a report accusing PolarityTE of being a “fraud.” The report alleges that the Company failed to disclose that the Company’s technology has been rejected by the U.S. Patent and Trademark Office. Based on this report, PolaryTE’s share price dropped significantly during intraday trading.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall, or Sherin Mahdavian, of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.
Sherin Mahdavian, Esq.

SOURCE: The Schall Law Firm

ReleaseID: 504044